mRNA Vaccines against Flaviviruses

The global distribution and burden of dengue

Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037 · cited 1× · see citing works

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works

SARS-CoV-2 vaccines in development

Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · see citing works

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · see citing works

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · see citing works

Antibody-dependent enhancement of severe dengue disease in humans

Katzelnick, L. C., Gresh, L., Halloran, M. E., Mercado, J. C., Kuan, G. M., Gordon, A. L., Balmaseda, Á., & Harris, E. (2017) · Science · doi:10.1126/science.aan6836 · Cited by 1,202 · see citing works

The continued threat of emerging flaviviruses

Pierson, T. C., & Diamond, M. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0714-0 · Cited by 1,111 · see citing works

Zika virus in the Americas: Early epidemiological and genetic findings

Faria, N. R., Azevedo, R. D. S. D. S., Kraemer, M. U. G., de Souza, R. P., Cunha, M. S., Hill, S. C., Thézé, J., Bonsall, M. B., Bowden, T. A., Rissanen, I., et al. (2016) · Science · doi:10.1126/science.aaf5036 · Cited by 1,084 · see citing works

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014 · see citing works

Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans

Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T., Supasa, S., et al. (2010) · Science · doi:10.1126/science.1185181 · Cited by 929 · see citing works

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909 · see citing works

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898 · see citing works

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884 · see citing works

The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency.

Gallie, D. R. (1991) · Genes & Development · doi:10.1101/gad.5.11.2108 · Cited by 868 · see citing works

Tick-borne encephalitis

Lindquist, L., & Vapalahti, O. P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60800-4 · Cited by 804 · see citing works

Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

Stettler, K., Beltramello, M., Espinosa, D. A., Graham, V., Cassotta, A., Bianchi, S., Zatta, F., Minola, A., Jaconi, S., Mele, F., et al. (2016) · Science · doi:10.1126/science.aaf8505 · Cited by 750 · see citing works

Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation

Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682 · see citing works

Tick-Borne Encephalitis

Kaiser, R. (2008) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2008.03.013 · Cited by 663 · see citing works

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642 · see citing works

Stability of Endogenous and Added RNA in Blood Specimens, Serum, and Plasma

Tsui, N. B. Y., Ng, E. K. O., & Lo, Y. D. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.10.1647 · Cited by 628 · see citing works

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · see citing works

A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA

Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569 · see citing works

Zika Virus Infection — After the Pandemic

Musso, D., Ko, A. I., & Baud, D. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1808246 · Cited by 560 · see citing works

The Flavivirus Precursor Membrane-Envelope Protein Complex: Structure and Maturation

Li, L., Lok, S., Yu, I.-M., Zhang, Y., Kuhn, R. J., Chen, J., & Rossmann, M. G. (2008) · Science · doi:10.1126/science.1153263 · Cited by 556 · see citing works

Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity

Bardina, S. V., Bunduc, P., Tripathi, S., Duehr, J. E., Frere, J. J., Brown, J. A., Nachbagauer, R., Foster, G. A., Krysztof, D. E., Tortorella, D., et al. (2017) · Science · doi:10.1126/science.aal4365 · Cited by 536 · see citing works

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530 · see citing works

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530 · see citing works

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Dejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jumnainsong, A., Edwards, C., Quyen, N. T. H., Duangchinda, T., et al. (2014) · Nature Immunology · doi:10.1038/ni.3058 · Cited by 504 · see citing works

Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses

Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501 · see citing works

The promise of mRNA vaccines: a biotech and industrial perspective

Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · cited 2× · see citing works

Self-amplifying RNA vaccines for infectious diseases

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487 · see citing works

Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered.

Halstead, S. B., Nimmannitya, S., & Cohen, S. N. (1970) · PubMed · Cited by 480 · see citing works

THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION

Theiler, M., & Smith, H. (1937) · The Journal of Experimental Medicine · doi:10.1084/jem.65.6.787 · Cited by 445 · see citing works

Protection against Japanese Encephalitis by Inactivated Vaccines

Hoke, C. H., Nisalak, A., Sangawhipa, N., Jatanasen, S., Laorakapongse, T., Innis, B. L., Kotchasenee, S.-O., Gingrich, J. B., Latendresse, J. R., Fukai, K., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809083191004 · Cited by 417 · see citing works

Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification

Balsitis, S. J., Williams, K. L., Lachica, R., Flores, D., Kyle, J. L., Mehlhop, E., Johnson, S., Diamond, M., Beatty, P. R., & Harris, E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000790 · Cited by 412 · see citing works

Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L

Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356 · see citing works

Receptors and routes of dengue virus entry into the host cells

Cruz-Oliveira, C., Freire, J. M., Conceição, T. M., Higa, L. M., Castanho, M. A. R. B., & Poian, A. T. D. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuu004 · Cited by 340 · see citing works

Efficient generation of human iPSCs by a synthetic self-replicative RNA

Yoshioka, N., Gros, E., Li, H.-R., Kumar, S., Deacon, D. C., Maron, C., Muotri, A. R., Chi, N. C., Fu, X.-D., Yu, B. D., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.001 · Cited by 312 · see citing works

Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH

Allison, S. L., Schalich, J., Stiasny, K., Mandl, C. W., Kunz, C., & Heinz, F. X. (1995) · Journal of Virology · doi:10.1128/jvi.69.2.695-700.1995 · Cited by 305 · see citing works

Japanese encephalitis

Yun, S.-I., & Lee, Y.-M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26902 · Cited by 288 · see citing works

Dengue Virus Ensures Its Fusion in Late Endosomes Using Compartment-Specific Lipids

Zaitseva, E., Yang, S., Melikov, K., Pourmal, S., & Chernomordik, L. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001131 · Cited by 287 · see citing works

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281 · see citing works

Zika virus infection enhances future risk of severe dengue disease

Katzelnick, L. C., Narvaez, C., Arguello, S., Mercado, B. L., Collado, D., Ampie, O., Elizondo, D., Miranda, T., Carrillo, F. A. B., Mercado, J. C., et al. (2020) · Science · doi:10.1126/science.abb6143 · Cited by 276 · see citing works

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease

Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A., Cao, B., Himansu, S., Caine, E. A., Nunes, B. T. D., Medeiros, D. B. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.040 · Cited by 267 · see citing works

The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design

Rey, F. A., Stiasny, K., Vaney, M. C., Dellarole, M., & Heinz, F. X. (2017) · EMBO Reports · doi:10.15252/embr.201745302 · Cited by 261 · see citing works

Update on Powassan Virus: Emergence of a North American Tick-Borne Flavivirus

Ebel, G. D. (2009) · Annual Review of Entomology · doi:10.1146/annurev-ento-112408-085446 · Cited by 240 · see citing works

Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells

Chareonsirisuthigul, T., Kalayanarooj, S., & Ubol, S. (2007) · Journal of General Virology · doi:10.1099/vir.0.82537-0 · Cited by 237 · see citing works

Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America

Hermance, M. E., & Thangamani, S. (2017) · Vector-Borne and Zoonotic Diseases · doi:10.1089/vbz.2017.2110 · Cited by 214 · see citing works

Structural basis for the preferential recognition of immature flaviviruses by a fusion‐loop antibody

Cherrier, M. V., Kaufmann, B., Nybakken, G. E., Lok, S., Warren, J. T., Chen, B. R., Nelson, C. A., Kostyuchenko, V. A., Holdaway, H. A., Chipman, P. R., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.245 · Cited by 213 · see citing works

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 212 · cited 1× · see citing works

Foreign nucleic acids as the stimulus to make interferon

Isaacs, A., Cox, R. A., & Rotem, Z. (1963) · The Lancet · doi:10.1016/s0140-6736(63)92585-6 · Cited by 211 · see citing works

Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age

Halstead, S. B. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.089 · Cited by 205 · see citing works

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202 · see citing works

How does Zika virus cause microcephaly?Preprint

Wen, Z., Song, H., & Ming, G. (2017) · Genes & Development · doi:10.1101/gad.298216.117 · Cited by 182 · see citing works

HPLC purification of in vitro transcribed long RNA

Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180 · see citing works

The Dual-Specific Binding of Dengue Virus and Target Cells for the Antibody-Dependent Enhancement of Dengue Virus Infection

Huang, K., Yang, Y., Lin, Y., Huang, J.-H., Liu, H., Yeh, T., Chen, S., Liu, H., & Lei, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2825 · Cited by 171 · see citing works

Historical Perspectives on Flavivirus Research

Holbrook, M. R. (2017) · Viruses · doi:10.3390/v9050097 · Cited by 162 · see citing works

An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model

Chahal, J. S., Fang, T., Woodham, A. W., Khan, O. F., Ling, J. J., Anderson, D. G., & Ploegh, H. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-00193-w · Cited by 161 · see citing works

A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika

Erasmus, J. H., Khandhar, A. P., Guderian, J., Granger, B., Archer, J., Archer, M., Gage, E., Fuerte-Stone, J., Larson, E., Lin, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.010 · Cited by 161 · see citing works

Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand

Kis, Z., Kontoravdi, C., Shattock, R. J., & Shah, N. (2020) · Vaccines · doi:10.3390/vaccines9010003 · Cited by 161 · see citing works

Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus

Fleeton, M. N., Chen, M., Berglund, P., Rhodes, G., Parker, S. E., Murphy, M., Atkins, G. J., & Liljeström, P. (2001) · The Journal of Infectious Diseases · doi:10.1086/319857 · Cited by 157 · see citing works

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin

Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L. M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01786-15 · Cited by 154 · see citing works

Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres

Plevka, P., Battisti, A. J., Junjhon, J., Winkler, D. C., Holdaway, H. A., Keelapang, P., Sittisombut, N., Kuhn, R. J., Steven, A. C., & Rossmann, M. G. (2011) · EMBO Reports · doi:10.1038/embor.2011.75 · Cited by 132 · see citing works

In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model

Mandl, C. W., Aberle, J. H., Aberle, S. W., Holzmann, H., Allison, S. L., & Heinz, F. X. (1998) · Nature Medicine · doi:10.1038/4031 · Cited by 124 · see citing works

An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections

VanBlargan, L. A., Himansu, S., Foreman, B. M., Ebel, G. D., Pierson, T. C., & Diamond, M. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.082 · Cited by 123 · see citing works

Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naïve and dengue exposed individuals

Henein, S., Swanstrom, J., Byers, A. M., Moser, J. M., Shaik, S. F., Bonaparte, M. I., Jackson, N., Guy, B., Baric, R. S., & de Silva, A. M. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw576 · Cited by 122 · see citing works

Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes

Ross, J., & Sullivan, T. (1985) · Blood · doi:10.1182/blood.v66.5.1149.1149 · Cited by 121 · see citing works

Progress and Works in Progress: Update on Flavivirus Vaccine Development

Collins, M. H., & Metz, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.07.001 · Cited by 121 · see citing works

Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis

Barbi, L., Coelho, A. V. C., de Alencar, L. C. A., & Crovella, S. (2018) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2018.02.005 · Cited by 120 · see citing works

A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses

Wollner, C. J., Richner, M., Hassert, M., Pinto, A. K., Brien, J. D., & Richner, J. M. (2021) · Journal of Virology · doi:10.1128/jvi.02482-20 · Cited by 119 · see citing works

A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens

Swaminathan, G., Thoryk, E. A., Cox, K. S., Meschino, S., Dubey, S. A., Vora, K. A., Celano, R., Gindy, M. E., Casimiro, D. R., & Bett, A. J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.132 · Cited by 118 · see citing works

Mimicking live flavivirus immunization with a noninfectious RNA vaccine

Kofler, R. M., Aberle, J. H., Aberle, S. W., Allison, S. L., Heinz, F. X., & Mandl, C. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307145101 · Cited by 116 · see citing works

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques

Pardi, N., LaBranche, C. C., Ferrari, G., Cain, D. W., Tombácz, I., Parks, R. J., Muramatsu, H., Mui, B. L., Tam, Y. K., Karikó, K., et al. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.03.003 · Cited by 103 · see citing works

Guillain–Barré Syndrome After Zika Virus Infection in Brazil

do Rosário, M. S., de Jesus, P. A. P., Vasilakis, N., Farias, D. S., Novaes, M. A. C., Rodrigues, S. G., Martins, L. C., Vasconcelos, P. F. D. C., Ko, A. I., Alcântara, L. C. J., et al. (2016) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0306 · Cited by 99 · see citing works

Zika Virus Vaccine: Progress and Challenges

Shan, C., Xie, X., & Shi, P. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.021 · Cited by 99 · see citing works

Twenty Years of Progress Toward West Nile Virus Vaccine Development

Kaiser, J. A., & Barrett, A. D. T. (2019) · Viruses · doi:10.3390/v11090823 · Cited by 97 · see citing works

Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease

Barrett, A. D. T. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.032 · Cited by 94 · see citing works

Humoral and Cellular Immune Response to RNA Immunization with Flavivirus Replicons Derived from Tick-Borne Encephalitis Virus

Aberle, J. H., Aberle, S. W., Kofler, R. M., & Mandl, C. W. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15107-15113.2005 · Cited by 91 · see citing works

Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice

Zhang, M., Sun, J., Li, M., & Jin, X. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.013 · Cited by 90 · see citing works

A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice

Roth, C., Cantaert, T., Colas, C., Prot, M., Casadémont, I., Levillayer, L., Thalmensi, J., Langlade‐Demoyen, P., Gerke, C., Bahl, K., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01424 · Cited by 84 · see citing works

Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin

Huysmans, H., Zhong, Z., De Temmerman, J., Mui, B. L., Tam, Y. K., Mc Cafferty, S., Gitsels, A., Vanrompay, D., & Sanders, N. N. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.08.001 · Cited by 83 · see citing works

Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins

Beißert, T., Koste, L., Perković, M., Walzer, K. C., Erbar, S., Selmi, A., Diken, M., Kreiter, S., Türeci, Ö., & Şahin, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.121 · Cited by 81 · see citing works

RIG-I and MDA-5 Detection of Viral RNA-dependent RNA Polymerase Activity Restricts Positive-Strand RNA Virus Replication

Nikonov, A., Mölder, T., Sikut, R., Kiiver, K., Männik, A., Toots, U., Lulla, A., Lulla, V., Utt, A., Merits, A., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003610 · Cited by 80 · see citing works

Development of a potent Zika virus vaccine using self-amplifying messenger RNA

Luisi, K., Morabito, K. M., Burgomaster, K. E., Sharma, M., Kong, W., Foreman, B. M., Patel, S., Fisher, B. E., Aleshnick, M., Laliberte, J. P., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba5068 · Cited by 80 · see citing works

Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine

Zhong, Z., Catani, J. P. P., Cafferty, S. M., Couck, L., Broeck, W. V. D., Gorlé, N., Vandenbroucke, R. E., Devriendt, B., Ulbert, S., Cnops, L., et al. (2019) · Vaccines · doi:10.3390/vaccines7030096 · Cited by 69 · see citing works

Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope

Metz, S., Thomas, A., White, L., Stoops, M., Corten, M., Hannemann, H., & de Silva, A. M. (2018) · Virology Journal · doi:10.1186/s12985-018-0970-2 · Cited by 68 · see citing works

Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization

Nelson, C. S., Jenks, J. A., Pardi, N., Goodwin, M. L., Roark, H. K., Edwards, W., McLellan, J. S., Pollara, J., Weissman, D., & Permar, S. R. (2020) · Journal of Virology · doi:10.1128/jvi.00186-20 · Cited by 60 · see citing works

Zika virus vaccines: immune response, current status, and future challenges

Richner, J. M., & Diamond, M. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.04.024 · Cited by 59 · see citing works

Trials and Tribulations on the Path to Developing a Dengue Vaccine

Thomas, S. J., & Rothman, A. L. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.09.006 · Cited by 50 · see citing works

Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses

Shirai, S., Kawai, A., Shibuya, M., Munakata, L., Omata, D., Suzuki, R., & Yoshioka, Y. (2020) · Vaccines · doi:10.3390/vaccines8030433 · Cited by 44 · see citing works

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?Preprint

de Silva, A. M., & Harris, E. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a029371 · Cited by 42 · see citing works

Experimenteller und epidemiologischer Beitrag zur aktiven Immunisierung gegen die Fr�hling-Sommer-Zeckenencephalitis

Smorodintseff, A. A., Kagan, N. W., LEVKOVICH, E. N., & Dankovsky, N. L. (1941) · Archives of Virology · doi:10.1007/bf01240711 · Cited by 37 · see citing works

A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity

Wollner, C. J., Richner, M., Hassert, M. A., Pinto, A. K., Brien, J. D., & Richner, J. M. (2021) · doi:10.1101/2021.01.05.425517 · Cited by 6 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

mRNA vaccines for infectious diseases — advances, challenges and opportunities

Pardi, N., & Krammer, F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01042-y · Cited by 246 · see citing works

mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications

Wang, Y., Kumari, M., Chen, G., Hong, M.-H., Yuan, J. P., Tsai, J.-L., & Wu, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 183 · see citing works

Recent Advancement in mRNA Vaccine Development and Applications

Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 177 · see citing works

Dengue: A Growing Problem With New Interventions

Wong, J. M., Adams, L. E., Durbin, A. P., Muñoz‐Jordán, J. L., Poehling, K. A., Sánchez‐González, L., Volkman, H. R., & Paz‐Bailey, G. (2022) · PEDIATRICS · doi:10.1542/peds.2021-055522 · Cited by 140 · see citing works

Current Developments and Challenges of mRNA Vaccines

Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 106 · see citing works

Current Advances in Zika Vaccine Development

Wang, Y., Ling, L., Zhang, Z., & Marín-López, A. (2022) · Vaccines · doi:10.3390/vaccines10111816 · Cited by 91 · see citing works

Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines

Sadeghian, I., Heidari, R., Sadeghian, S., Raee, M. J., & Negahdaripour, M. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106094 · Cited by 54 · see citing works

Current status and perspectives on vaccine development against dengue virus infection

Park, J., Kim, J., & Jang, Y. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1625-y · Cited by 49 · see citing works

Tick-Borne Encephalitis—Review of the Current Status

Kwaśnik, M., Rola, J., & Rożek, W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206603 · Cited by 48 · see citing works

A review on Zika vaccine development

Peng, Z., Yang, S., Lu, H., Wang, L., Li, N., Zhang, H., Xing, S.-Y., Du, Y., & Deng, S. (2024) · Pathogens and Disease · doi:10.1093/femspd/ftad036 · Cited by 35 · see citing works

Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future

Bello, M. B., Alsaadi, A., Naeem, A., Almahboub, S. A., Bosaeed, M., & Aljedani, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1475886 · Cited by 37 · see citing works

A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice

He, L., Sun, W., Yang, L., Liu, W., & Li, J. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.07.003 · Cited by 32 · see citing works

Advances in mRNA and other vaccines against MERS-CoV

Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 32 · see citing works

Vaccine development for mosquito-borne viral diseases

Huang, Z., Zhang, Y., Li, H., Zhu, J., Song, W., Chen, K., Zhang, Y., & Lou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161149 · Cited by 32 · see citing works

Engineering Modified mRNA-Based Vaccine against Dengue Virus Using Computational and Reverse Vaccinology Approaches

Mukhtar, M., Wajeeha, A. W., Zaidi, N. U. S. S., & Bibi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213911 · Cited by 30 · see citing works

Virulence and Immune Evasion Strategies of FMDV: Implications for Vaccine Design

Medina, G. N., & Segundo, F. D.-S. (2024) · Vaccines · doi:10.3390/vaccines12091071 · Cited by 23 · see citing works

Novel approaches for the rapid development of rationally designed arbovirus vaccines

van Bree, J. W. M., Visser, I., Duyvestyn, J. M., Aguilar-Bretones, M., Marshall, E. M., van Hemert, M. J., Pijlman, G. P., van Nierop, G. P., Kikkert, M., Rockx, B., et al. (2023) · One Health · doi:10.1016/j.onehlt.2023.100565 · Cited by 17 · see citing works

mRNA vaccine development and applications: A special focus on tumors (Review)

Chen, B., Yang, Y., Wang, X., Yang, W., Lu, Y., Wang, D., Zhuo, E., Tang, Y., Su, J., Tang, G., et al. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5669 · Cited by 16 · see citing works

Dengue and Flavivirus Co-Infections: Challenges in Diagnosis, Treatment, and Disease Management

Sabrina, R. S. A., Azami, N. A. M., & Yap, W. B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146609 · Cited by 16 · see citing works

Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review

Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16 · see citing works

Current development of Zika virus vaccines with special emphasis on virus-like particle technology

Cimica, V., Galarza, J. M., Rashid, S., & Stedman, T. T. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1945447 · Cited by 14 · see citing works

mRNA Innovates the Vaccine Field

Pardi, N. (2021) · Vaccines · doi:10.3390/vaccines9050486 · Cited by 14 · see citing works

West Nile Virus: Epidemiology, Surveillance, and Prophylaxis with a Comparative Insight from Italy and Iran

Najafi, S., Jojani, M., Najafi, K., Costanzo, V., Vicidomini, C., & Roviello, G. N. (2026) · Vaccines · doi:10.3390/vaccines14010057 · Cited by 11 · see citing works

Research progress of mosquito-borne virus mRNA vaccines

Sun, N., Su, Z., & Zheng, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101398 · Cited by 11 · see citing works

Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses

Baric, T. J., & Reneer, Z. B. (2024) · Viruses · doi:10.3390/v17010001 · Cited by 10 · see citing works

Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue

Kumari, M., Su, S.-C., Lin, H.-T., Ko, S.-H., Lu, Y.-F., Chen, K.-C., Wy, C., Wu, M.-J., & Wu, H. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127216 · Cited by 9 · see citing works

Potential of mRNA vaccines to become versatile cancer vaccines

Tsao, S. Y. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i8.663 · Cited by 8 · see citing works

Interactions of host miRNAs in the flavivirus 3´UTR genome: From bioinformatics predictions to practical approaches

Avila‐Bonilla, R. G., & Salas-Benito, J. S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.976843 · Cited by 8 · see citing works

Virus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development

Castilho, L. R., de Mattos, N. R., Abreu, W. S., & Gutarra, M. L. E. (2022) · Biologics · doi:10.3390/biologics2040018 · Cited by 7 · see citing works

From Recoding to Peptides for MHC Class I Immune Display: Enriching Viral Expression, Virus Vulnerability and Virus Evasion

Atkins, J. F., O’Connor, K. M., Bhatt, P. R., & Loughran, G. (2021) · Viruses · doi:10.3390/v13071251 · Cited by 7 · see citing works

Coming of age: mRNA vaccines for orthoflaviviruses

Akther, F., Pardi, N., & Martinez, D. R. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.10.005 · Cited by 3 · see citing works

Orthoflavivirus Vaccine Platforms: Current Strategies and Challenges

Unali, G., & Douam, F. (2025) · Vaccines · doi:10.3390/vaccines13101015 · Cited by 3 · see citing works

Attenuating Mutations in Usutu Virus: Towards Understanding Orthoflavivirus Virulence Determinants and Live Attenuated Vaccine Design

Duyvestyn, J. M., Bredenbeek, P. J., Gruters, M. J., Taş, A., Nelemans, T., Kikkert, M., & van Hemert, M. J. (2025) · Vaccines · doi:10.3390/vaccines13050495 · Cited by 2 · see citing works

Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines

Park, J. Y., & Lee, H. (2025) · Vaccines · doi:10.3390/vaccines13121182 · Cited by 2 · see citing works

The Dengue Vaccine Initiative: A Bibliometric Analysis of Research Publications

Mulakoli, F., Ongeso, A., & Musembi, H. M. (2024) · Infectious diseases · doi:10.5772/intechopen.1006040 · Cited by 1 · see citing works

RNA therapeutics for infectious diseases

Tu, L. M. T. P. P. L. M., Pham, T. T. D., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.002 · Cited by 1 · see citing works

The importance of the role of T-cell immunity in the development of modern tick-borne encephalitis vaccines

Tigeeva, E. V., Nizolenko, L. F., & Карпенко, Л. И. (2024) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-553 · Cited by 1 · see citing works

Vaccines and Neglected Tropical Diseases: a complicated challenge or a postpandemic hope

Diego, J. G.-B., Manzano-Román, R., & Muro, A. (2022) · Anales de la Real Academia Nacional de Farmacia · doi:10.53519/analesranf.2022.88.05.22

Flaviviruses: Dengue

Thomas, S. J., Endy, T. P., & Rothman, A. L. (2023) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_15-1

In silico strategies for predicting therapeutic peptides targeting the capsid protein of the dengue virus

Dixit, N. K., & Kumar, A. (2024) · Journal of Proteins and Proteomics · doi:10.1007/s42485-024-00165-5

Development of a Tick-Borne Encephalitis Virus Nanoparticle Vaccine Utilizing Envelope DimerPreprint

Wang, B., & Zhao, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.13.622924

Vaccines and Immune Response to Orthoflavivirus: Challenges and Advances

Climaco-Arvizu, S., & Gutiérrez‐Sánchez, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012373

Coming of age: mRNA vaccines for orthoflaviviruses

Akther, F., Pardi, N., & Martinez, D. R. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.10.005 · Cited by 3 · see citing works

Opportunities and Challenges of mRNA and VLP Technologies for Pan-Flavivirus Vaccine Development: Focus on Conserved Quaternary Epitope Conformations

Burgos, E., Camacho-Ortega, S. J., Atkinson, B., Chua, J. V., & Heredia, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021081 · Cited by 2 · see citing works

mRNA vaccines for viral diseases: mechanism, advances, and future perspective

Chakraborty, B., & Singh, T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11856-1 · Cited by 1 · see citing works

One mRNA Vaccine to Rule Them All

Staff, E. (2022) · Molecular Medicine Communications · doi:10.55627/mmc.002.02.0164

Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family

Wong, S. H., Jassey, A., Wang, J. Y., Wang, W.-C., Liu, C., & Lin, L. (2019) · Vaccines · doi:10.3390/vaccines7040123 · Cited by 24 · see citing works